Factors influencing thrombin generation measured as thrombin-antithrombin complexes levels and using calibrated automated thrombogram in patients with advanced coronary artery disease;Czynniki wpłwaja̧ce na generacjȩ trombiny mierzona̧ jako stȩżenie kompleksów trombina- antytrombina i metoda̧ automatycznego skalibrowanego trombogramu u chorych z zaawansowana̧ choroba̧ wieńcowa̧

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 7, 2007, Pages 297-305

  Stȩpień, Ewa ^a   Plicner, Dariusz ^a   Branicka, Agnieszka ^a   Stankiewicz, Elzbieta ^a   Pazdan, Agnieszka ^a   Śniezek Maciejewska, Maria ^b   Górkiewicz, Izabela ^a   Kapelak, Bogusław ^b   Sadowski, Jerzy ^a  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Calibrated automated thrombogram; Coronary artery disease; Thrombin generation; Thrombin antithrombin complex

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA THROMBOGLOBULIN; C REACTIVE PROTEIN; FIBRINOGEN; HEMOSTATIC AGENT; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TRANSACTIVATOR PROTEIN; ANTITHROMBIN;

ADULT; AGE; AGED; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY OCCLUSION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOMATION; BLOOD CLOTTING; CALIBRATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; EPICARDIUM; FEMALE; FIBRINOGEN BLOOD LEVEL; GENDER; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROTEIN BLOOD LEVEL; STABLE ANGINA PECTORIS; THROMBOGENESIS; THROMBOSIS; BIOSYNTHESIS; BLOOD; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBINS; BETA-THROMBOGLOBULIN; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; THROMBIN;

EID: 35348944491     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Meade TW, Mellows S, Miller GJ, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Hart Study. Lancet. 1986; 2: 533-538.
2. Folsom AR, Wu KK, Rosamond WD, et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997; 96: 1102-1108.
3. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation. 1996; 94: 1226-1232.
4. Ardissino D, Merlini PA, Bauer KA, et al. Thrombogenic potential of human coronary atherosclerotic plaques. Blood. 2001; 98: 2726-2729.
5. Páramo JA, Orbe J, Beloqui O, et al. Prothrombin fragment 1 +2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke. 2004; 35: 1085-1089.
6. Aleil B, Meyer N, Wolff V, et al. Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost. 2006; 96: 505-511.
7. Stȩpień E, Szułdrzyński K, Branicka A, et al. Allel PlA1/A2 beta3 integryny wia̧że siȩ ze zwiȩkszona̧, generacja̧, trombiny u pacjentów z choroba̧ wieńcowá leczonych aspiryna̧ - wpływ leczenia statynami. Pol Arch Med Wewn. 2007; 1-2: 33-40.
8. Aronson DL, Stevan L, Ball AP, et al. Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma. J Clin Invest. 1977; 60: 1410-1418.
9. Hoek JA, Sturk A, Cats JW, et al. Laboratory and clinical evaluation of an assay of thrombin-antithrombin III complexes in plasma. Clin Chem. 1988; 34: 2058-2062.
10. Chuang YJ, Swanson R, Raja SM, et al. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem. 2001; 276: 14961-14971.
11. de Bosch NB, Mosesson MW, Ruiz-Sáez A, et al. Inhibition of thrombin generation in plasma by fibrin formation (Antithrombin I). Thromb Haemost. 2002; 88: 253-258.
12. Bajzar L, Nesheim M, Morser J, et al. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998; 273: 2792-2798.
13. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007; 109: 2285-2292.
14. Romano M, Guagnano MT, Pacini G, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab. 2003; 88: 5321-5326.
15. Bauer KA, Weiss LM, Sparrow D, et al. Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest. 1987; 80: 1527-1534.
16. Rosendaal FR, van Hylckama Vlieg HA, et al. Estrogens, progestogens and thrombosis. J Thromb Haemost. 2003; 1: 1371-1380.
17. Aoki I, Shimoyama K, Aoki N, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol. 1996; 27: 560-566.
18. Corseaux D, Ollivier V, Fontaine V, et al. Hemostasis imbalance in experimental hypertension. Mol Med. 2002; 8: 169-178.
19. Musiał, J, Paja̧k A, Undas A, et al. Thrombin generation markers and coronary heart disease risk factors in a Polish population sample. Thromb Haemost. 1997; 77: 697-700.
20. Hemker HC, Wielders S, Kessels H, et al. Continuous registration of thrombin-generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost. 1993; 70: 617-624.
21. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002; 32: 249-253.
22. Cassar K, Bachoo P, Ford I, et al. Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2005; 29: 171-176.
23. Marcucci R, Gori AM, Giannotti F, et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemost. 2006; 4: 1017-1022.
24. Psuja P, Zozulinska M, Turowiecka Z, et al. Plasma markers of hypercoagulability in patients with serious infections and risk of septic shock. Clin Appl Thromb Hemost. 2002; 8: 225-230.
25. Ono N, Koyama T, Suehiro A, et al. Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke patients. Stroke. 1991; 22: 1369-1373.
26. Undas A, Brummel K, Musial J. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001; 103: 2248-2253.
27. Undas A, Celinska-Löwenhoff M, Brummel-Ziedins KE, et al. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V, and enhance factor Va inactivation in hypercnolesterolemic patients. Arterioscler Thromb Vasc Biol. 2005; 25: 1524-1525.
28. Vanschoonbeek K, Feijge MAH, Paquay M, et al. Variable hypocoagulant effect of fish oilintake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol. 2004; 24: 1734-1740.
29. Reganon E, Vila V, Martinez-Sales V, et al. Inflammation, fibrinogen and thrombin generation in patients with previous myocardial infarction. Haematologica. 2002; 87: 740-745.
30. Niccoli G, Biasucci LM, Biscione C, et al. Instability mechanisms in unstable angina according to baseline serum levels of C-reactive protein: The role of thrombosis, fibrinolysis and atherosclerotic burden. Int J Cardiol. 2007 Jan 29; [Epub ahead of print].
31. Undas A, Plicner D, Stȩpień E, et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost. 2007; 5: 1988-1990.
32. Butenas S, Mann KG. Caution in the interpretation of continuous thrombin generation assays. J Thromb Haemost. 2007; 5: 1084-1085.
33. Villanueva GB, Allen N. Acetylation of antithrombin III by aspirin. Semin Thromb Hemost. 1986; 12: 213-215.
34. Schaeffer G, Wascher TC, Kostner GM, et al. Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia. 1999; 42: 167-176.
35. Rabini RA, Staffolani R, Fumelli P, et al. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia. 1998; 41: 101-104.